March 15, 2024
Loading...
You are here:  Home  >  'Novartis'  -  Page 2
Latest

CVS Health will not cover Amgen’s Neupogen in favor of Novartis biosimilar

By   /  Thursday, August 4th, 2016  /  Health Care & Life Science, Latest news  /  Comments Off on CVS Health will not cover Amgen’s Neupogen in favor of Novartis biosimilar

CVS Health will no longer cover Thousand Oaks-based Amgen’s Neupogen on its standard drug plan in 2017, favoring the biosimilar Zarxio from Novartis. CVS, which is the second largest benefits manager behind Express Scripts and also owns the largest chain of drug stores in the U.S., said Aug. 2 it will choose biosimilar drugs over Read More →

Latest

FDA declines to approve Novartis biosimilar for Amgen’s Neulasta

By   /  Tuesday, July 19th, 2016  /  Health Care & Life Science, Latest news  /  Comments Off on FDA declines to approve Novartis biosimilar for Amgen’s Neulasta

The Food and Drug Administration has declined for now to approve a copycat version of Amgen’s blockbuster drug Neulasta. Reuters reported July 19 that the FDA sent a letter to Swiss pharmaceutical Novartis at the end of June saying it was declining to approve the drug for now. Neulasta, made by Thousand Oaks-based biotech giant Read More →

Latest

Amgen wins one, loses one in biosimilar battle

By   /  Friday, July 15th, 2016  /  East Ventura County, Health Care & Life Science, left, Technology  /  Comments Off on Amgen wins one, loses one in biosimilar battle

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Latest

Amgen’s new drug for migraines shows promise

By   /  Thursday, June 9th, 2016  /  Health Care & Life Science, Latest news  /  Comments Off on Amgen’s new drug for migraines shows promise

Thousand Oaks-based Amgen said a drug being developed in collaboration with Novartis showed promising results in providing relief for patients suffering from chronic migraines. The Phase 2 clinical trial met benchmarks for migraine reduction at two levels of dosage and with limited side effects. “Migraine is the sixth-leading cause of disability worldwide. Three to seven Read More →

Latest

Thousand Oaks’ Amgen just keeps chugging along

By   /  Friday, February 5th, 2016  /  Earnings, East Ventura County, Health Care & Life Science, middle, Tri-County Public Companies  /  Comments Off on Thousand Oaks’ Amgen just keeps chugging along

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Latest

Novartis biosimilar works as well as Amgen’s Neulasta

By   /  Monday, December 7th, 2015  /  Health Care & Life Science, Latest news, Tri-County Public Companies  /  Comments Off on Novartis biosimilar works as well as Amgen’s Neulasta

Swiss pharmaceutical Novartis announced Monday that a copycat version of Amgen’s Neulasta works just as well to prevent a condition that can lead to infection in women with breast cancer. Neulasta stimulates white blood cell production in the body, which helps the body fight cancer. Novartis’ new drug is part of a new class of Read More →

Latest

Amgen bipolar about biosimilars

By   /  Friday, December 4th, 2015  /  Health Care & Life Science, Latest news, Top Stories, Tri-County Public Companies  /  Comments Off on Amgen bipolar about biosimilars

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.